# Cryoport, Inc.: financial statements, quarterly

CYRX · Nasdaq · CIK 1124524 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyrx.md) · [Financials](/companies/cyrx/financials.md) · [Filings](/companies/cyrx/filings.md) · [Insiders](/companies/cyrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cyrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [56.2](/filings/0001558370-24-014896.md) | [(7.3) d](/filings/0001104659-26-024180.md) | [37.3](/filings/0001558370-25-007012.md) | [39.7](/filings/0001558370-25-011127.md) | [38.3](/filings/0001104659-25-107640.md) | [41.5 d](/filings/0001104659-26-024180.md) | [41.0](/filings/0001104659-26-055513.md) | [45.5](/filings/0001104659-26-092107.md) | [44.2](/filings/0001104659-25-107640.md) | [45.5 d](/filings/0001104659-26-024180.md) | [47.8](/filings/0001104659-26-055513.md) | [49.0](/filings/0001104659-26-092107.md) |
| Cost of revenue | $m | [31.9](/filings/0001558370-24-014896.md) | [(6.6) d](/filings/0001104659-26-024180.md) | [22.2](/filings/0001558370-25-007012.md) | [22.0](/filings/0001558370-25-011127.md) | [20.9](/filings/0001104659-25-107640.md) | [22.0 d](/filings/0001104659-26-024180.md) | [22.4](/filings/0001104659-26-055513.md) | [24.1](/filings/0001104659-26-092107.md) | [22.9](/filings/0001104659-25-107640.md) | [23.7 d](/filings/0001104659-26-024180.md) | [25.9](/filings/0001104659-26-055513.md) | [26.1](/filings/0001104659-26-092107.md) |
| Gross profit | $m | [24.3](/filings/0001558370-24-014896.md) | [(0.7) d](/filings/0001104659-26-024180.md) | [15.1](/filings/0001558370-25-007012.md) | [17.7](/filings/0001558370-25-011127.md) | [17.4](/filings/0001104659-25-107640.md) | [19.5 d](/filings/0001104659-26-024180.md) | [18.6](/filings/0001104659-26-055513.md) | [21.4](/filings/0001104659-26-092107.md) | [21.3](/filings/0001104659-25-107640.md) | [21.7 d](/filings/0001104659-26-024180.md) | [21.9](/filings/0001104659-26-055513.md) | [22.8](/filings/0001104659-26-092107.md) |
| Research and development | $m | [5.2](/filings/0001558370-24-014896.md) | [4.7 d](/filings/0001104659-26-024180.md) | [4.8](/filings/0001558370-25-007012.md) | [4.6](/filings/0001558370-25-011127.md) | [4.2](/filings/0001104659-25-107640.md) | [4.2 d](/filings/0001104659-26-024180.md) | [3.9](/filings/0001104659-26-055513.md) | [4.1](/filings/0001104659-26-092107.md) | [4.5](/filings/0001104659-25-107640.md) | [4.5 d](/filings/0001104659-26-024180.md) | [3.9](/filings/0001104659-26-055513.md) | [4.9](/filings/0001104659-26-092107.md) |
| Selling, general and administrative | $m | [36.0](/filings/0001558370-24-014896.md) | [0.2 d](/filings/0001104659-26-024180.md) | [27.8](/filings/0001558370-25-007012.md) | [27.2](/filings/0001558370-25-011127.md) | [26.7](/filings/0001104659-25-107640.md) | [28.1 d](/filings/0001104659-26-024180.md) | [21.9](/filings/0001104659-26-055513.md) | [26.9](/filings/0001104659-26-092107.md) | [26.7](/filings/0001104659-25-107640.md) | [27.3 d](/filings/0001104659-26-024180.md) | [27.6](/filings/0001104659-26-055513.md) | [28.0](/filings/0001104659-26-092107.md) |
| Operating income | $m | [(16.9)](/filings/0001558370-24-014896.md) | [(55.3) d](/filings/0001104659-26-024180.md) | [(17.5)](/filings/0001558370-25-007012.md) | [(78.0)](/filings/0001558370-25-011127.md) | [(13.4)](/filings/0001104659-25-107640.md) | [(12.7) d](/filings/0001104659-26-024180.md) | [(7.2)](/filings/0001104659-26-055513.md) | [(9.6)](/filings/0001104659-26-092107.md) | [(9.9)](/filings/0001104659-25-107640.md) | [(10.0) d](/filings/0001104659-26-024180.md) | [(9.6)](/filings/0001104659-26-055513.md) | [(10.0)](/filings/0001104659-26-092107.md) |
| Interest expense | $m | [1.4](/filings/0001558370-23-018511.md) | [1.3 d](/filings/0001558370-24-003128.md) | [1.3](/filings/0001558370-24-007133.md) | [1.2](/filings/0001558370-25-011127.md) | [0.9](/filings/0001104659-25-107640.md) | [0.6 d](/filings/0001104659-26-024180.md) | [0.6](/filings/0001104659-26-055513.md) | [0.6](/filings/0001104659-26-092107.md) | [0.5](/filings/0001104659-25-107640.md) | [0.6 d](/filings/0001104659-26-024180.md) | [0.4](/filings/0001104659-26-055513.md) | [0.5](/filings/0001104659-26-092107.md) |
| Income tax | $m | [0.5](/filings/0001558370-24-014896.md) | [(1.3) d](/filings/0001104659-26-024180.md) | [0.1](/filings/0001558370-25-007012.md) | [0.1](/filings/0001558370-25-011127.md) | [0.3](/filings/0001104659-25-107640.md) | [(0.1) d](/filings/0001104659-26-024180.md) | [0.2](/filings/0001104659-26-055513.md) | [0.3](/filings/0001104659-26-092107.md) | [0.2](/filings/0001104659-25-107640.md) | [1.1 d](/filings/0001104659-26-024180.md) | [0.1](/filings/0001104659-26-055513.md) | [0.5](/filings/0001104659-26-092107.md) |
| Net income | $m | [(13.3)](/filings/0001558370-24-014896.md) | [(62.4) d](/filings/0001104659-26-024180.md) | [(18.9)](/filings/0001558370-25-007012.md) | [(78.0)](/filings/0001558370-25-011127.md) | [0.8](/filings/0001104659-25-107640.md) | [(18.7) d](/filings/0001104659-26-024180.md) | [(12.0)](/filings/0001104659-26-055513.md) | [109](/filings/0001104659-26-092107.md) | [(6.9)](/filings/0001104659-25-107640.md) | [(11.6) d](/filings/0001104659-26-024180.md) | [(10.5)](/filings/0001104659-26-055513.md) | [(8.3)](/filings/0001104659-26-092107.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001558370-24-014896.md) | not reported | [(0.43)](/filings/0001558370-25-007012.md) | [(1.62)](/filings/0001558370-25-011127.md) | [(0.02)](/filings/0001104659-25-107640.md) | not reported | [(0.28)](/filings/0001104659-26-055513.md) | [2.13](/filings/0001104659-26-092107.md) | [(0.18)](/filings/0001104659-25-107640.md) | not reported | [(0.25)](/filings/0001104659-26-055513.md) | [(0.20)](/filings/0001104659-26-092107.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001558370-24-014896.md) | not reported | [(0.43)](/filings/0001558370-25-007012.md) | [(1.62)](/filings/0001558370-25-011127.md) | [(0.02)](/filings/0001104659-25-107640.md) | not reported | [(0.28)](/filings/0001104659-26-055513.md) | [2.13](/filings/0001104659-26-092107.md) | [(0.18)](/filings/0001104659-25-107640.md) | not reported | [(0.25)](/filings/0001104659-26-055513.md) | [(0.20)](/filings/0001104659-26-092107.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.5](/filings/0001558370-23-018511.md) | [35.2](/filings/0001104659-26-024180.md) | [39.3](/filings/0001558370-25-007012.md) | [34.2](/filings/0001558370-25-011127.md) | [31.4](/filings/0001104659-25-107640.md) | [34.1](/filings/0001104659-26-092107.md) | [36.1](/filings/0001104659-26-055513.md) | [243](/filings/0001104659-26-092107.md) | [256](/filings/0001104659-25-107640.md) | [250](/filings/0001104659-26-092107.md) | [273](/filings/0001104659-26-055513.md) | [269](/filings/0001104659-26-092107.md) |
| Current assets | $m | [549](/filings/0001558370-23-018511.md) | [535](/filings/0001558370-25-002509.md) | [526](/filings/0001558370-24-007133.md) | [502](/filings/0001558370-24-011562.md) | [350](/filings/0001558370-24-014896.md) | [342](/filings/0001104659-26-024180.md) | [411](/filings/0001558370-25-007012.md) | [489](/filings/0001558370-25-011127.md) | [485](/filings/0001104659-25-107640.md) | [476](/filings/0001104659-26-092107.md) | [471](/filings/0001104659-26-055513.md) | [460](/filings/0001104659-26-092107.md) |
| Total assets | $m | [1,001](/filings/0001558370-23-018511.md) | [958](/filings/0001558370-25-002509.md) | [943](/filings/0001558370-24-007133.md) | [852](/filings/0001558370-24-011562.md) | [702](/filings/0001558370-24-014896.md) | [703](/filings/0001104659-26-024180.md) | [700](/filings/0001558370-25-007012.md) | [774](/filings/0001558370-25-011127.md) | [774](/filings/0001104659-25-107640.md) | [765](/filings/0001104659-26-092107.md) | [764](/filings/0001104659-26-055513.md) | [756](/filings/0001104659-26-092107.md) |
| Current liabilities | $m | [44.9](/filings/0001558370-23-018511.md) | [45.6](/filings/0001558370-25-002509.md) | [49.0](/filings/0001558370-24-007133.md) | [59.9](/filings/0001558370-24-011562.md) | [61.4](/filings/0001558370-24-014896.md) | [64.6](/filings/0001104659-26-024180.md) | [74.0](/filings/0001558370-25-007012.md) | [30.1](/filings/0001558370-25-011127.md) | [30.7](/filings/0001104659-25-107640.md) | [219](/filings/0001104659-26-092107.md) | [225](/filings/0001104659-26-055513.md) | [221](/filings/0001104659-26-092107.md) |
| Total liabilities | $m | [463](/filings/0001558370-23-018511.md) | [469](/filings/0001558370-25-002509.md) | [471](/filings/0001558370-24-007133.md) | [452](/filings/0001558370-24-011562.md) | [283](/filings/0001558370-24-014896.md) | [302](/filings/0001104659-26-024180.md) | [301](/filings/0001558370-25-007012.md) | [259](/filings/0001558370-25-011127.md) | [261](/filings/0001104659-25-107640.md) | [262](/filings/0001104659-26-092107.md) | [269](/filings/0001104659-26-055513.md) | [266](/filings/0001104659-26-092107.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [538](/filings/0001558370-24-014896.md) | [489](/filings/0001104659-26-024180.md) | [472](/filings/0001558370-25-011127.md) | [400](/filings/0001104659-25-107640.md) | [419](/filings/0001104659-25-107640.md) | [402](/filings/0001104659-26-092107.md) | [399](/filings/0001104659-26-092107.md) | [519](/filings/0001104659-26-092107.md) | [513](/filings/0001104659-25-107640.md) | [503](/filings/0001104659-26-092107.md) | [495](/filings/0001104659-26-092107.md) | [491](/filings/0001104659-26-092107.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.0) d](/filings/0001558370-24-014896.md) | [2.5 d](/filings/0001104659-26-024180.md) | [(3.3)](/filings/0001558370-25-007012.md) | [(8.0) d](/filings/0001558370-25-011127.md) | [0.4 d](/filings/0001104659-25-107640.md) | [(5.5) d](/filings/0001104659-26-024180.md) | [(4.3)](/filings/0001104659-26-055513.md) | [(7.3) d](/filings/0001104659-26-092107.md) | [2.2 d](/filings/0001104659-25-107640.md) | [0.9 d](/filings/0001104659-26-024180.md) | [3.7](/filings/0001104659-26-055513.md) | [1.1 d](/filings/0001104659-26-092107.md) |
| Capital expenditure | $m | [9.0 d](/filings/0001558370-24-014896.md) | [11.6 d](/filings/0001104659-26-024180.md) | [4.0](/filings/0001558370-25-007012.md) | [3.8 d](/filings/0001558370-25-011127.md) | [4.2 d](/filings/0001104659-25-107640.md) | [5.2 d](/filings/0001104659-26-024180.md) | [3.2](/filings/0001104659-26-055513.md) | [4.4 d](/filings/0001104659-26-092107.md) | [3.5 d](/filings/0001104659-25-107640.md) | [5.5 d](/filings/0001104659-26-024180.md) | [10.0](/filings/0001104659-26-055513.md) | [9.1 d](/filings/0001104659-26-092107.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.7 d](/filings/0001104659-25-107640.md) | [2.0 d](/filings/0001104659-26-024180.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.5](/filings/0001558370-23-018511.md) | [48.4](/filings/0001558370-24-007133.md) | [48.7](/filings/0001558370-24-011562.md) | [48.9](/filings/0001558370-24-014896.md) | [49.0](/filings/0001558370-25-007012.md) | [49.3](/filings/0001558370-25-011127.md) | [49.4](/filings/0001104659-25-107640.md) | [49.9](/filings/0001104659-26-055513.md) | [50.3](/filings/0001104659-26-092107.md) | [50.1](/filings/0001104659-25-107640.md) | [49.9](/filings/0001104659-26-055513.md) | [50.4](/filings/0001104659-26-092107.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 50,649,100 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092107.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.